News

Marco Ruo of Marchesini noted worth €1m, the packaging line will demonstrate the hardware and software that is required by pharmaceutical customers to comply with industry regulations for

Temple University is the original owner of the RHB-102 patents. Previously RedHill Biopharma had reported that Scolr Pharma, which originally licensed certain patents to RedHill Biopharma for RHB-102,

The guidance does not include patients with highly active MS. The guidance published by the SMC represents an important step in improving the standard of care available to

No dose-limiting safety issues and no serious adverse events have been reported in the dose-escalation stage. Based on these encouraging safety and tolerability results, BioLineRx will proceed with

Obtained in a collaborative project with the US-based Paragon Bioservices, the data showed that CAP cells were able to produce very high titers of RSV. When compared to

The DSMC met to review available patient data as part of the planned interim analysis, scheduled to occur following 222 patient events. The DSMC, following its review, recommended

C3 Jian’s C16G2 is a synthetic peptide derived from the company’s pheromone signaling platform technology referred to as STAMPs (specifically targeted antimicrobial peptides). The drug targets the specific

Genentech is currently marketing Xeloda in the US. Teva claims that it was the first to receive approval on its abbreviated new drug application from the US Food

The research group of Dr Francesco Saverio Tedesco from the UCL department of Cell and Developmental Biology is conducting the research, which is being supported through funding of